Some bispecific antibody therapies link immune T cells directly to cancer cells. One arm of the bispecific attaches to a T cell. The other arm attaches to the cancer cell. This connection activates the T cell to release proteins that kill the cancer cell.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.